Related Experiment Videos
[A clinical study on cefdinir in pediatrics]
Insights
Cefdinir (CFDN) demonstrated an 88% efficacy rate in treating pediatric infections, with a low incidence of side effects. This suggests CFDN is a safe and effective antibiotic option for children.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Antimicrobial Therapy
Background:
- Pediatric infections pose a significant public health challenge.
- Evaluating novel antimicrobial agents for pediatric use is crucial.
- Cefdinir (CFDN) is a third-generation cephalosporin antibiotic.
Purpose of the Study:
- To assess the clinical efficacy and safety of cefdinir (CFDN) in pediatric patients.
- To evaluate the bacteriological eradication rates associated with CFDN treatment.
- To document adverse events and abnormal laboratory findings during CFDN therapy.
Main Methods:
- Clinical evaluations were conducted on 43 pediatric patients with various infections.
- Bacteriological assessments included evaluating eradication rates for 34 pathogen isolates.
- Adverse events and laboratory parameters were monitored throughout the study.
Main Results:
- An overall clinical efficacy rate of 88% was observed (23 excellent, 15 good, 4 fair).
- The bacteriological eradication rate for targeted pathogens was 85.3%.
- Diarrhea occurred in 8.3% of patients; abnormal lab findings included elevated GOT, eosinophils, and platelets.
Conclusions:
- Cefdinir (CFDN) exhibits high clinical efficacy and a favorable safety profile in treating pediatric infections.
- The drug achieved significant bacteriological eradication, supporting its effectiveness against common pediatric pathogens.
- CFDN is a promising and safe therapeutic option for managing infections in pediatric populations.
Abstract:
Clinical evaluations of cefdinir (CFDN, FK482) were carried out. The obtained results are summarized as follows. 1. Clinical responses to CFDN of 43 patients with pediatric infections were excellent in 23, good in 15, fair in 4 and poor in 1. The overall efficacy rate was 88%. 2. Bacteriologically, the eradication rate for 34 isolates presumed to be pathogens was evaluated and the eradication rate was 85.3%. 3. Side effects observed were diarrhea in 4 of 48 patients. The incidence was 8.3%. Abnormal laboratory findings were an elevation of GOT, an elevation of eosinophils and an increase in platelet counts. The results suggested that CFDN might be a very useful and safe drug for the treatment of pediatric infections.